Patents by Inventor Kaida Wu

Kaida Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
    Patent number: 11931420
    Abstract: The present disclosure relates to methods of using antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs in combination with a gamma secretase inhibitor (GSI), such as in therapeutic methods. Also provided are pharmaceutical compositions and kits comprising the antibody conjugates and GSI.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 19, 2024
    Assignee: CELGENE CORPORATION
    Inventor: Kaida Wu
  • CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF
    Publication number: 20230190798
    Abstract: Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as non-Hodgkin's lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a B-cell non-Hodgkin lymphoma (B-cell NHL). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as CD 19, on cells of the lymphoma.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 22, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Robert Guy CASPARY, Calvin CHAN, Divya VARUN, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Keenan BASHOUR, Oleksandr BATUREVYCH, Nurgul KILAVUZ, Kristen HEGE, Michael BURGESS, Kaida WU, Ruth Amanda SALMON
  • BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF
    Publication number: 20230087953
    Abstract: Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as multiple myeloma (MM), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a relapsed or refractory multiple myeloma (r/r MM). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as BCMA, on cells of the myeloma.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 23, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Robert Guy CASPARY, Calvin CHAN, Divya VARUN, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Keenan BASHOUR, Oleksandr BATUREVYCH, Nurgul KILAVUZ, Kristen HEGE, Michael BURGESS, Kaida WU, Ruth Amanda SALMON, Ashley KOEGEL
  • COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI)
    Publication number: 20220401569
    Abstract: The present disclosure relates to methods of using antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs in combination with a gamma secretase inhibitor (GSI), such as in therapeutic methods. Also provided are pharmaceutical compositions and kits comprising the antibody conjugates and GSI.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 22, 2022
    Applicant: CELGENE CORPORATION
    Inventor: Kaida WU
  • Migrastatin analogs in the treatment of cancer
    Patent number: 8957056
    Abstract: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: February 17, 2015
    Assignee: Sloan-Kettering Instiute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson, Malcolm A. S. Moore, Kaida Wu, David C. Dorn, Mihirbaran Mandal
  • Synthesis of epothilones, intermediates thereto, analogues and uses thereof
    Patent number: 7875638
    Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: January 25, 2011
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Alexey Rivkin, Fumihiko Yoshimura, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong, Kaida Wu, Malcolm A. S. Moore, David Dorn
  • Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof
    Publication number: 20090149516
    Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).
    Type: Application
    Filed: June 9, 2008
    Publication date: June 11, 2009
    Inventors: Samuel J. Danishefsky, Alexey Rivkin, Fumihiko Yoshimura, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong, Kaida Wu, Malcolm A.S. Moore, David Dorn
  • Migrastatin analogs in the treatment of cancer
    Publication number: 20090124662
    Abstract: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.
    Type: Application
    Filed: May 25, 2006
    Publication date: May 14, 2009
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson, Malcolm A.S. Moore, Kaida Wu, David C. Dorn, Mihirbaran Mandal
  • Synthesis of epothilones, intermediates thereto, analogues and uses thereof
    Patent number: 7384964
    Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: June 10, 2008
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Alexey Rivkin, Fumihiko Yoshimura, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong, Kaida Wu, Malcolm A. S. Moore, David Dorn
  • Synthesis of epothilones, intermediates thereto, analogues and uses thereof
    Publication number: 20050143429
    Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).
    Type: Application
    Filed: August 18, 2004
    Publication date: June 30, 2005
    Inventors: Samuel Danishefsky, Alexey Rivkin, Fumihiko Yoshimura, Ting-Chao Chou, Ana Gabarda, Huajin Dong, Kaida Wu, Malcolm Moore, David Dorn